Literature DB >> 9537589

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells.

K Sharma1, C B Srikant.   

Abstract

Somatostatin (SST) analogs inhibit tumor cell growth by exerting direct anti-proliferative effects with cytostatic (growth arrest) or cytotoxic (apoptosis) consequences. The SST analog SMS 201-995 (octreotide, OCT) inhibits growth of MCF-7 human breast adenocarcinoma cells, which express multiple SSTRs. Its action has been reported to result in either apoptosis or growth arrest, but the underlying mechanisms have not been elucidated in this tumor cell model. Here, we report that OCT elicits cytotoxic response in these cells, leading to apoptosis, which is associated with a rapid, time-dependent induction of wild-type p53 and an increase in Bax. There was no G1 cell-cycle arrest in these cells during OCT treatment as suggested by the decrease in G1/S ratio and the lack of induction of pRb and p21. Additionally, we demonstrate that OCT-induced DNA fragmentation in this cell line is due to selective activation of a cation-insensitive acidic endonuclease. Our data provide a rationale for utilizing SST analogs to treat SSTR-positive breast cancer cells expressing wild-type p53.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537589     DOI: 10.1002/(sici)1097-0215(19980413)76:2<259::aid-ijc14>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

2.  Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells.

Authors:  Yuan Zhang; Xueqing Wang; Jiancheng Wang; Xuan Zhang; Qiang Zhang
Journal:  Pharm Res       Date:  2011-02-22       Impact factor: 4.200

3.  Correlation between expression of gastrin, somatostatin and cell apoptosis regulation gene bcl-2/bax in large intestine carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Xiang-Hou Xia; Ji-Qun Hu; Wen-Bin Huang; Guo-Qiang Xu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

4.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

5.  A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells.

Authors:  Z Szegedi; J Takács; B Szende; Z Vadász; A Horváth; E Gulyás; G Tóth; I Peták; J Bocsi; G Kéri
Journal:  Endocrine       Date:  1999-02       Impact factor: 3.633

6.  Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.

Authors:  H L Watt; Z Rachid; B J Jean-Claude
Journal:  J Neurooncol       Date:  2010-05-14       Impact factor: 4.130

7.  Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors.

Authors:  Marie-Louise Fjällskog; Eva Ludvigsen; Mats Stridsberg; Kjell Oberg; Barbro Eriksson; Eva T Janson
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

8.  Somatostatin and cancer: applying endocrinology to oncology.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2004-08-23       Impact factor: 4.742

9.  Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro.

Authors:  Jing-Hua Wang; Quan-Tai Xing; Meng-Biao Yuan
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

Review 10.  Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

Authors:  Quanri Jin; Francisco J Esteva
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.